Advanced glycation end products (AGEs)
  atherosclerosis role 168
  dietary sources 202, 203
  formation 168
  platelet phosphatidylserine
    externalization induction 171, 172
  signaling 173
  toxicity 317
Albumin, removal of protein-bound solutes 178–182
Alcohol, cardiovascular disease risks in dialysis patients 225
Aluminum binders 269, 270
Anemia
  cardiovascular disease risks in dialysis patients 227, 235
  Dialysis Outcomes and Practice Patterns
    Study management 62, 64
Angiotensin-converting enzyme (ACE)
  inhibitors, cardiovascular disease benefits in hemodialysis patients 4
Anthropometry, total body water estimation 159
Apo E4, cardiovascular disease risks in dialysis patients 223
Arterial compliance
  definition 307, 308
  flow-mediated dilatation 309
  pulse wave analysis
    aortic pressure reconstruction 312
    aortic pulse analysis 311, 312
    augmentation index 312, 313
  finger plethysmography 312
  physiological considerations 310
  tonometry 312
  transfer function 311
  pulse wave velocity 307–309
Artificial kidney, see Wearable artificial kidney
Atherosclerosis
  advanced glycation end product role 169
  malnutrition, inflammation, and atherosclerosis syndrome 200, 201
  oxidative stress role 251–253
  platelet phosphatidylserine externalization role 169
  vascular calcification, see Vascular calcification
Beta-blockers, cardiovascular disease benefits in hemodialysis patients 5
Biocompatibility, cardiovascular disease risks in dialysis patients 234
Bioelectrical impedance analysis (BIA), see also Segmental bioimpedance
  body fluid volume assessment
    equations 153, 154
    techniques 152
  definition 163
  electrical properties of tissues 151, 152
  postdialysis target body weight optimization 150, 151
  spectroscopy 163
vector bioelectrical impedance analysis
accuracy 154
impedance correlation with
ultrafiltration 159
optimal current frequency 159
principles 151–153
tissue hydration classification 158, 159
vector patterns
adequate versus inadequate vector
trajectories 158
hemodialysis cycle 155, 156
normal versus abnormal vector
trajectories 156–158
steady state 154, 155
volume-dependent hypertension and
hypotension 159
wet-dry weight prescription 160

Biopharmaceutical
definition 289
generic versions, see Biosimilars
immunogenicity 291, 292
production and characterization 290,
291
stability 291
structural complexity 289, 290

Biosimilars
definition 289
regulation 292, 293

Blood flow, control and monitoring in
hemodialysis 25
Blood viscosity, shear rate effects 13–15
Body size, HEMO Study subgroup
analysis 75
Body weight
obesity and cardiovascular disease risks
in dialysis patients 224
postdialysis target body weight
optimization, see Bioelectrical
impedance analysis
Bone morphogenetic protein-7 (BMP-7),
deficiency and vascular calcification
281, 282

Calcimimetic agents, vascular calcification
prevention 276
Calcium
parathyroid hormone regulation 265–268

vascular calcification, see Vascular
calcification
Calcium channel blockers, cardiovascular
disease benefits in hemodialysis
patients 5
3-Carboxy-4-methyl-5-propyl-2-
furanpropionic acid (CMPF)
morbidity role in dialysis 177, 178
removal of protein-bound solute 178, 179
Central venous pressure, total body water
estimation 159, 160
Coffee, caffeine consumption and
cardiovascular mortality in dialysis
patients 204, 205
Congestive heart failure (CHF), slow
continuous intravenous plasmapheresis
clinical feasibility study 336–339
Continuous renal replacement therapy
(CRRT)
advantages 325, 326
artificial kidney, see Wearable artificial
kidney
slow continuous intravenous
plasmapheresis, see Slow continuous
intravenous plasmapheresis
slow continuous ultrafiltration, see Slow
continuous ultrafiltration

Convection
diffusion interference 15, 16
solute convective flux equation 122
C-reactive protein (CRP)
cardiovascular disease
direct promotion by C-reactive protein
186–188
risk detection
end-stage renal disease 189, 190
general population 188, 189
gene polymorphisms 191, 192
interleukin-6 level correlation in
end-stage renal disease 186
statin reduction 189, 192–194

p-Cresol
cardiovascular disease risks in dialysis
patients 234
morbidity role in dialysis 177,
178, 318, 319
removal of protein-bound solute 178–181
Depression
  cardiovascular disease impact in hemodialysis patients 3, 226
Dialysis Outcomes and Practice Patterns Study findings 65
Diabetes, cardiovascular disease risks in dialysis patients 224
Dialysate
  channeling prevention 15
  control and monitoring
    composition 23–25
    flow 25
  delivery system 20, 21
  water quality, see Water treatment
Dialysis Outcomes and Practice Patterns Study (DOPPS)
  anemia management 62, 64
  background 58, 59, 94, 95
  depression findings 65
  nutrition and mineral metabolism practices 59–62
  statin outcomes 64, 65
  vascular access use and outcomes 65, 66
Dialysis Outcomes Quality Initiative (DOQI), development 94
Diet, see Nutrition
Diffusion
  convection interference 15, 16
  diffusivity
    coefficient 12, 13
    effects on sieving 12, 13
    solute diffusive flux equation 12
Dilutometry, total body water estimation 160
Dinucleoside polyphosphates, uremic toxicity 320
Dyslipidemia, cardiovascular disease risks in dialysis patients 223, 224, 234
Electrocardiography, potassium removal rates and arrhythmia effects 297, 299, 300, 302, 303
End-stage renal disease (ESRD)
  cardiovascular mortality 92
  demographic trends 6, 91
  epidemiology 90, 91
  geographic distribution 91
  mortality determinants 92, 93
Exercise, inactivity and cardiovascular disease risks in dialysis patients 225
Extracorporeal circuit
  hemoconcentration measurement 38
  overview 19–21
  pressure measurement 39, 40
  solute concentration measurement
    local measurement 36
    perturbation 36, 37
    resolution 36
    sampling rate 36
    sodium 37, 38
  temperature monitoring 38, 39
Fetuin, see α2-Heremans-Schmid glycoprotein
Fluid overload, cardiovascular disease risks in dialysis patients 222, 223
Generic drug, definition 287–289
Hemodiafiltration (HDF), see also Mid-dilution hemodiafiltration
  advantages 108
  hemodialysis comparison studies 112
  predilution versus postdilution 108, 109
  sequential hemofiltration-hemodiafiltration, see Sequential hemofiltration-hemodiafiltration
Hemodialysis machines, see also Extracorporeal circuit
  control and monitoring 24, 25
  dialysate delivery system 20, 21
  disinfection 22
  extracorporeal circuit 19–22
  hazards and safety 22–24
  overview 18, 19
  ultrafiltration control 21, 22, 25
Hemofiltration (HF)
  advantages 52
  comparative trial with ultrapure bicarbonate dialysis
    blood chemistry 54–57
    intratreatment hemodynamics 54, 57
    morbidity 54, 57
    study design 52, 53
    survival 53, 54
sequential hemofiltration-
hemodiafiltration, see Sequential
hemofiltration-hemodiafiltration

HEMO Study
background 69–72
dialysis dose expressions 77, 78
high-flux dialysis findings 84–86, 11
secondary end points 79–81
subgroup analysis
body size 75
comorbidity 72, 73
prevalent versus incident patients 74, 75
sex differences 75, 76

α2-Heremans-Schmid glycoprotein
(AHSG), deficiency and vascular
calcification 282, 283

Homocysteine
cardiovascular disease risks in dialysis
patients 204, 221, 222
vitamin D deficiency and secondary
hypertension 268

Infection, cardiovascular disease risks in
dialysis patients 227, 228

Inflammation, see also C-reactive protein
cardiovascular disease risks in dialysis
patients 185, 186, 227, 228
causes in end-stage renal disease 190, 191
genetic susceptibility in end-stage renal
disease 191, 192
malnutrition, inflammation, and
atherosclerosis syndrome 200, 201
nutrition interactions
diet effects on inflammation 202–206
inflammation effect on nutritional
status 201, 202
pathogenesis 201
statin reduction 189, 192–194
water quality effects 42, 43

Interleukin-6 (IL-6)
C-reactive protein level correlation in
end-stage renal disease 186
gene polymorphisms 191

Internal filtration (IF)
governing principles 27–29
mathematical modeling
applications 34
design and implementation 30, 31
simulations 31–33

Interventional nephrology (IN)
challenges 135, 136
needs 132, 133
overview 131, 132
percutaneous balloon angioplasty
access stenosis management 143, 144
complication rates 146, 147
percutaneous bone biopsy 134, 135
peritoneal dialysis catheter placement
133, 134
professional organizations 135
program establishment 133
renal ultrasound 133
thrombectomy for access thrombosis
144, 145
tunneled catheter procedures 134, 145,
146
vascular access responsibilities
complication management 127, 128,
134, 143–146
documentation and quality measures
128, 129
education and training 129
first access placement 123, 126,
127, 134
organization of care 128
patient education 139, 140
planning 140
predialysis period
access surgeon referral 122, 123
ultrasound evaluation 122, 126
surveillance and monitoring
123, 124
vascular mapping 141–143

Kidney Disease: Improving Global
Outcomes (KDIGO)
development 95–97
goals 95
website 96

Kidney Disease Outcomes Quality Initiative
(K/DOQI), development 94

KoA
definition 11
variation with flow distribution 12
Kt/V
control and monitoring 25
inadequacy and cardiovascular disease risks in dialysis patients 224
long nocturnal hemodialysis 104
wearable artificial kidney 330, 331

Lanthanum carbonate, vascular calcification prevention 276
Left ventricular hypertrophy (LVH), kidney disease relationship 93
Leptin
cardiovascular disease risks in dialysis patients 234
malnutrition role in hemodialysis patients 202
morbidity role in dialysis patients 177

Lipopolysaccharide (LPS)
effects on monocyte phenotype and apoptosis 213–216
endotoxin removal from dialysis water 235

Lipoprotein(a), cardiovascular disease risks in dialysis patients 223

Long nocturnal hemodialysis
Kt/V 104
morbidity 102–105
mortality 101, 102, 104
rationale 100
study design 101
switching to short hemodialysis 103

Matrix Gla protein (MGP), deficiency and vascular calcification 283, 284

Mediterranean diet, cardiovascular benefits 205

Membraneless dialysis
ambulatory dialyzer prospects apparatus 349–35
performance 349
concept 344
microfluidic transport 344–346
molecular transport studies in blood 351
plasmapheresis prospects 351
preventing cells from sheath fluid entry 348
recirculating sheath concept 346–348

Membrane Permeability Outcome (MPO)
study
background 87
baseline data analysis 87, 88

Membranes
cardiovascular risk factor 234, 235
functions 344
limitations in dialysis 344

Mid-dilution hemodiafiltration (MD HDF)
advantages compared with high-flux hemodialysis 112, 113
clearance outcomes 110
rationale 108, 109
study design 109, 110

Monocytes
apoptosis 212, 213
CD14 expression in hemodialysis 211, 213, 215
CD16 expression in hemodialysis 211, 213
cytokine measurements 211, 213
lipopolysaccharide effects on phenotype and apoptosis 213–216
telomere shortening and senescence in hemodialysis
flow cytometry 211–213
overview 209, 210

Mortality
determinants in end-stage renal disease 92, 93
hemodialysis patients 2, 3, 83, 84, 296
long nocturnal hemodialysis 101, 102, 104

Nocturnal hemodialysis, see Long nocturnal hemodialysis

Nutrition
advanced glycation end product intake 202, 203
caffeine reduction 204, 205

Nutrition (continued)
Dialysis Outcomes and Practice Patterns Study practices 59–62
inflammation interactions
diet effects on inflammation 202–206
inflammation effect on nutritional status 201, 202
isoflavones 205
malnutrition, inflammation, and atherosclerosis syndrome 200, 201
omega-3 fatty acids and cardiovascular disease prevention in dialysis patients 225
uremic malnutrition and cardiovascular disease risks in dialysis patients 226, 227
vitamins 203, 204

Obesity, cardiovascular disease risks in dialysis patients 224

Oxidative stress, see also Reactive oxygen species
antioxidant defenses 249, 250
biomarkers 246–248
cell damage mechanisms 245, 246
nutrition and inflammation interactions 203, 204
pathogenesis
  Alzheimer’s disease 256
  atherosclerosis 251–253
  autoimmune disease 257
  stroke 256, 257
  uremic syndrome 253, 254, 256
reactive oxygen species contributors 244, 245
signaling 246–248
Ozone formation 242

Parathyroid hormone (PTH)
calcium regulation 265–268
derangements and cardiovascular disease risks in dialysis patients 6, 226
elevation in renal failure 267, 268
phosphate regulation 262
renal osteodystrophy management 269, 270
Phenylacetic acid, uremic toxicity 319, 320
Phosphate
binders 264, 265, 276
homeostasis control 263, 264
parathyroid hormone regulation 262
parathyroid hyperplasia regulation 262, 263
removal, wearable artificial kidney 331
Platelets, phosphatidylserine externalization
advanced glycation end product induction 171
atherosclerosis role 169
end-stage renal disease patients
  patient serum incubation effects 170
  patient studies 170
measurement 169, 170
Potassium
derangements and arrhythmias 296, 297
removal rates and arrhythmia effects
electrocardiography 297, 299
premature ventricular contractions 299, 300, 302, 303
statistical analysis 299, 304
study design 297–299
removal, wearable artificial kidney 331
Premature ventricular contractions (PVCs), potassium removal rates and arrhythmia effects 299, 300, 302, 303
Pulse wave analysis
aortic pressure reconstruction 312
aortic pulse analysis 311, 312
augmentation index 312, 313
finger plethysmography 312
physiological considerations 310
tonometer 312
transfer function 311

Reactive oxygen species (ROS), see also Oxidative stress
antioxidant defenses 249, 250
biological species 241, 242
cell damage mechanisms 245, 246
free radical formation 240, 241
oxidative stress contributors 244, 245
reduction potentials 243, 244
sources 246, 247
Renal osteodystrophy, integrated management 269, 270
Risk factors, cardiovascular disease in dialysis patients, see also specific risk factors
dialysis components
  dialyzer and membrane 234, 235
  monitoring 236, 237
treatment modality 235, 236
water quality 235
Risk factors, (continued)
modifiable risk factors 220–227
potentially modifiable risk factors 227, 228
total risk assessment 231–234

Scribner, Belding, observations on first hemodialysis 1, 2
Segmental bioimpedance
body composition assessment 163, 164
calf measurements 165, 166
definition 163
dry weight assessment 164–166
Sequential hemofiltration-hemodiafiltration (SHF-HDF)
advantages 118, 119
ease of operation 118
rationale 116
study design 116, 117
treatment efficacy quantification 117, 118
Sevelamer, vascular calcification prevention 276
Sheath dialysis, see Membraneless dialysis
Slow continuous intravenous plasmapheresis (SCIP)
animal studies 335, 336
backflush cycle 340
clinical feasibility study in congestive heart failure 336–339
indications 339–341
Slow continuous ultrafiltration (SCUF)
animal studies 335, 336
indications 339
Smoking, cardiovascular disease risks in dialysis patients 220, 221
Sodium, measurement in extracorporeal circuit 37, 38
Solute clearance, factors affecting it 11
Soy, cardiovascular benefits 205
Statins
cardiovascular disease benefits in hemodialysis patients 4
Dialysis Outcomes and Practice Patterns Study outcomes 64, 65
inflammation reduction 189, 192–194
Stress, cardiovascular disease risks in dialysis patients 226
Telomere shortening
cellular senescence 209
monocytes in hemodialysis flow cytometry 211–213
overview 209, 210
Ultrafiltration (UF)
control and monitoring 21, 22, 25, 236, 237
mechanisms along low-flux and high-flux dialyzers 28, 29
Ultrasound
renal ultrasound 133
vascular access evaluation 122, 126
vascular calcification 274
Uremia
definition 175
oxidative stress role in uremic syndrome 253, 254, 256
protein-bound solutes in uremic syndrome
removal 178–182
role 176–178
toxicity 318, 319
toxins and toxicity
advanced glycation end products 318
dinucleoside polyphosphates 320
guanidino compounds 316–319
peptides 320, 321
phenylacetic acid 319, 320
Vascular access (VA)
Dialysis Outcomes and Practice Patterns
Study use and outcomes 65, 66
interdisciplinary approach 125
nephrologist responsibilities, see also Interventional nephrology
complication management 127, 128
documentation and quality measures 128, 129
education and training 129
first access placement 123, 126, 127
organization of care 128
predialysis period
access surgeon referral 122, 123
ultrasound evaluation 122, 126
surveillance and monitoring 123, 124
prospects for study 129, 130
Vascular calcification
cardiovascular mortality outcomes 274, 275
detection 274
distribution within artery 272
pathology and etiopathogenesis
  bone morphogenetic protein-7 deficiency 281, 282
  α2-Heremans-Schmid glycoprotein deficiency 282, 283
  matrix Gla protein deficiency 283, 284
overview 273, 274, 280, 281, 284, 285
prevention
calcimimetic agents 276
calcium-based phosphate binders 276
  lanthanum carbonate 276
  Sevelamer 276
Vector bioelectrical impedance analysis,
  see Bioelectrical impedance analysis
Vitamin C, deficiency and inflammation 203
Vitamin D
deficiency and secondary hypertension 268
  resistance in renal failure 268, 269
Vitamin E, cardiovascular disease benefits in hemodialysis patients 6
Water treatment
  AAMI (Association for the Advancement of Medical Instrumentation) standards 43–45
  cardiovascular disease risks in dialysis patients 235
disinfection 48
  European Pharmacopoeia standards 43–45
  inflammation and water quality 42, 43
optimal system 45, 46
  quality assurance 48
  reverse osmosis 45, 46
  ultrapure dialysate preparation 46, 47
Wearable artificial kidney (WAK)
animal studies 327, 328
designs 329, 330
limitations 329
  mineral removal 330, 331
requirements 326, 327
  weekly Kt/V 330, 331